Wang, Andrew ZYuet, KaiZhang, LiangfangGu, Frank XHuynh-Le, MinhRadovic-Moreno, Aleksandar FKantoff, PhilipBander, Neil HLanger, RobertFarokhzad, Omid2016-10-132010Wang, Andrew Z, Kai Yuet, Liangfang Zhang, Frank X Gu, Minh Huynh-Le, Aleksandar F Radovic-Moreno, Philip W Kantoff, Neil H Bander, Robert Langer, and Omid C Farokhzad. 2010. “ChemoRad Nanoparticles: a Novel Multifunctional Nanoparticle Platform for Targeted Delivery of Concurrent Chemoradiation.” Nanomedicine 5 (3) (April): 361–368. doi:10.2217/nnm.10.6.1743-5889http://nrs.harvard.edu/urn-3:HUL.InstRepos:29005178Aim: The development of chemoradiation – the concurrent administration of chemotherapy and radiotherapy – has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation. Method: A biodegradable and biocompatible lipid–polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated. Results: Using docetaxel, indium111 and yttrium90 as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs. Conclusion: We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.en-USBiologically Targeted NanoparticleChemoRad NPChemoradiationChemoradiation NanoparticleNanomedicineNanotechnologyProstate CancerJournal Article2016-10-1310.2217/nnm.10.6